PHASE I TRIAL OF ENALAPRIL IN CHILDREN WITH HYPERTENSION
$0M01FY2002RRNIH
Weill Medical College Of Cornell Univ, New York NY
Investigators
Linked publications & trials
Paper 22292110Paper 20977343Paper 19906219Paper 19391080Paper 19017985Paper 18097152Paper 17316097Paper 17079285Paper 16763388Paper 16339698Paper 15526720Paper 15270860Paper 14962217Paper 14703595Paper 14625263Paper 14581545Paper 12654942Paper 12525204Paper 12468338Paper 12442030Paper 12393516Paper 12027270Paper 11967296Paper 11880731Paper 11821496Paper 11781358Paper 11605171Paper 11391167Paper 11335777Paper 11335753Paper 11170984Paper 11135346Paper 11085758Paper 11075607Paper 10912545Paper 10880061Paper 10807191Paper 10783035
Abstract
Angiotensin-converting enzyme inhibitors (ACEI) are widely used for the treatment of pediatric hypertension, and yet there have been very few prospective controlled studies reported. This protocol is part of a multicentric effort to establish a dose-response relationship for enalapril in children age 6 to 18. We will also investigate the safety and tolerability of enalapril in this group and we will define the response of surrogate markers for matrix metabolism o ACEI.
View original record on NIH RePORTER →